Market Research Report Respiratory Complications Therapeutics MarketTrend | Page 2

The respiratory therapy area contains numerous primary indications, including
asthma, COPD, CF and idiopathic pulmonary fibrosis (IPF), which have large
prevalent populations. In addition, there are many secondary respiratory conditions
that have smaller prevalent populations yet significant unmet clinical needs. This
report focuses on these secondary respiratory conditions, particularly pneumonia,
respiratory syncytial virus (RSV), pulmonary arterial hypertension (PAH) and
tuberculosis (TB).
A major cause of secondary respiratory disease is infections caused by bacteria or
viruses. Bacterial infections, such as pneumonia and TB, and viral infections, such
as RSV, cause infection of the lungs. The immune system response to these
infections causes inflammation that interferes with the ability of the lungs to
function. Cardiovascular problems also represent another major cause of respiratory
complications. PAH in particular represents a profound risk factor for cardiovascular
events in the pulmonary vascular system, including pulmonary embolism.
Overall, there are 843 products in active development in the respiratory
complications pipeline. However, this total constitutes many individual indications,
most of which are typically relatively small in terms of the number of pipeline
products in development. Pneumonia, TB, RSV and PAH are the secondary
conditions with the largest development pipelines.
Scope
 The respiratory complications market already contains commercially
successful products.
 Which classes of drug dominate the market?
 What additional benefits have newly approved therapies brought to the
market?
 The respiratory complications pipeline is large, with significant diversity in
terms of molecule types and targets.
 Which molecular targets appear most frequently in the pipeline?
 What are the commercial prospects for the most promising late-stage pipeline
products.
 The respiratory complications market is forecast to grow from $21.8 billion
in 2015 to $30.2 billion in 2022, at a compound annual growth rate of 4.7%.
 Which products are forecast to drive this substantial growth?